All terms and conditions of Roche's offer remain unchanged, it said in a statement on Monday.
(Reporting by John Miller; editing by Thomas Seythal)
Swiss drugmaker Roche again extended its offer for shares of gene therapy specialist Spark Therapeutics to Dec. 16 as a regulatory review of the $4.3 billion (3.35 billion pounds) transaction drags on.
All terms and conditions of Roche's offer remain unchanged, it said in a statement on Monday.
(Reporting by John Miller; editing by Thomas Seythal)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
402 USD | +0.34% | +1.08% | 112B | ||
221.4 CHF | +0.66% | -1.73% | 194B | ||
97.93 CHF | -0.07% | -7.62% | 31.23B | ||
1st Jan change | Capi. | |
---|---|---|
-2.70% | 102B | |
+2.22% | 96.07B | |
-1.69% | 21.66B | |
-17.46% | 20.77B | |
-7.01% | 18.53B | |
-40.31% | 16.91B | |
-28.39% | 13.79B | |
+0.15% | 13.33B | |
+20.63% | 10.94B |